Abrocitinib Long-Term Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study

被引：0

作者：

Reich, Kristian ^{[1
]}

Silverberg, Jonathan I. ^{[2
]}

de Bruin-Weller, Marjolein ^{[3
]}

Deleuran, Mette ^{[4
]}

Beck, Lisa A. ^{[5
]}

Papp, Kim ^{[6
]}

Farooqui, Saleem A. ^{[7
]}

Zhang, Fan ^{[8
]}

Feeney, Claire ^{[9
]}

Koppensteiner, Herwig ^{[10
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

[3] Univ Med Ctr Utrecht, Utrecht, Netherlands

[4] Aarhus Univ Hosp, Aarhus, Denmark

[5] Univ Rochester, Med Ctr, Rochester, NY USA

[6] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada

[7] Pfizer R&D UK Ltd, Sandwich, Kent, England

[8] Pfizer Inc, Groton, CT USA

[9] Pfizer Ltd, Tadworth, Surrey, England

[10] Pfizer Corp Austria GmbH, Vienna, Austria

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

44042

引用

页码：AB116 / AB116

页数：1

共 50 条

[1] Long-term management of moderate-to-severe atopic dermatitis with abrocitinib: a phase III extension study (JADE EXTEND)
Reich, K.
Silverberg, J. I.
Papp, K.
Deleuran, M.
Katoh, N.
Strober, B.
Beck, L. A.
de Bruin-Weller, M.
Werfel, T.
Zhang, F.
Biswas, P.
DiBonaventura, M.
Chan, G. L.
Farooqui, S. A.
Kerkmann, U.
Clibborn, C.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E141 - E142
[2] Influence of Baseline Disease Severity Defined by Investigator's Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
Gooderham, Melinda
Simpson, Eric
Geng, Bob
Gold, Linda F. Stein
Wollenberg, Andreas
Farooqui, Saleem A.
Zhang, Fan
Feeney, Claire
Watkins, Melissa
Koppensteiner, Herwig
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB181 - AB181
[3] Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND
Paller, Amy S.
Cork, Michael J.
Flohr, Carsten
Bangert, Christine
Weidinger, Stephan
Nesnas, John
Farooqui, Saleem A.
Biswas, Pinaki
Watkins, Melissa
Koppensteiner, Herwig
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[4] Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial
Alexis, Andrew F.
Deleuran, Mette
Silverberg, Jonathan, I
Gooderham, Melinda J.
Farooqui, Saleem A.
Chan, Gary
Koppensteiner, Herwig
Biswas, Pinaki
Watkins, Melissa
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[5] Protocol for an ongoing, phase III multicentre, long-term extension study investigating the long-term safety and efficacy of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE EXTEND)
Simpson, E. L.
Reich, K.
Silverberg, J. I.
Nasir, A.
Criado, P. R.
Biswas, P.
Koppensteiner, H.
Fan, D.
Rojo, R.
Farooqui, S. A.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E159 - E159
[6] Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
Reich, Kristian
Silverberg, Jonathan I.
Papp, Kim A.
Deleuran, Mette
Katoh, Norito
Strober, Bruce
Beck, Lisa A.
de Bruin-Weller, Marjolein
Werfel, Thomas
Zhang, Fan
Biswas, Pinaki
DiBonaventura, Marco D.
Chan, Gary
Johnson, Susan
Farooqui, Saleem A.
Kerkmann, Urs
Clibborn, Claire
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : 2056 - 2066
[7] Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
Gooderham, Melinda J.
Weidinger, Stephan
Simpson, Eric L.
Deleuran, Mette
Gold, Linda F. Stein
Farooqui, Saleem A.
Biswas, Pinaki
Chan, Gary
Guler, Erman
Koppensteiner, Herwig
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II32 - II33
[8] Abrocitinib in the treatment of moderate-to-severe atopic dermatitis refractory to dupilumab treatment: an analysis of JADE-EXTEND (a phase III long-term extension study)
Shi, V.
Bhutani, T.
Deleuran, M.
Fonacier, L.
Shumack, S.
Zhang, F.
Cameron, M. C.
Chan, G.
Valdez, H.
Yin, N.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E138 - E138
[9] Abrocitinib in the treatment of moderate-to-severe atopic dermatitis refractory to dupilumab treatment: An analysis of JADE-EXTEND, a phase 3 long-term extension study
Shi, Vivian
Bhutani, Tina
Deleuran, Mette
Fonacier, Luz
Shumack, Stephen
Zhang, Fan
Cameron, Michael C.
Chan, Gary
Valdez, Hernan
Yin, Natalie
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB36 - AB36
[10] Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long Term Extension Study
Shi, Vivian Y.
Bhutani, Tina
Deleuran, Mette
Fonacier, Luz
Shumack, Stephen
Zhang, Fan
Cameron, Michael C.
Chan, Gary
Valdez, Hernan
Yin, Natalie
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 78

← 1 2 3 4 5 →